The New Jersey Economic Development Authority's next public Board Meeting will be held on Thursday, November 17, 2016 at 10 a.m. at the EDA offices at 36 West State Street, Trenton. A copy of the proposed agenda can be found prior to the meeting at www.njeda.gov/Board. Following the Board Meeting, minutes and the full agenda will also be available at www.njeda.gov/Board.

  

TRENTON (November 10, 2016) – Union County-based Kiswe Mobile is devoted to providing sports enthusiasts with an innovative way of watching their favorite games. The Murray Hill technology company’s mobile app lets users customize their viewing experience through a variety of features including real-time sporting events, multiple camera angles and player-tracking technology. The app, which is available on both iOS and Android products, also enables sports fans to share their favorite clips via email or social media, live chat with other users, create customized television channels, and watch archives of completed games.
 
This summer, Kiswe partnered with Univision, the largest broadcast audience of any Spanish language television network in the world, to be the exclusive web-streaming broadcaster of the COPA America soccer tournament. Kiswe Co-Founder Wim Sweldens noted that the tournament, which culminated in the final at MetLife Stadium in East Rutherford, was a success, and Kiswe drove substantial traffic to Univision's web platform. Kiswe also partners with such organizations as the Women’s National Basketball Association’s Washington Mystics, the National Hockey League, and Steven’s Institute of Technology to bring a range of sporting events to app users.
 
Along with Swelden’s and Kiswe Chairman Jeong Kim’s leadership, the company has benefitted from more than $13 million in investments made through the State’s Angel Investor Tax Credit Program. Administered by the New Jersey Economic Development Authority (EDA) in consultation with the New Jersey Division of Taxation, the program offers a 10 percent refundable tax credit against New Jersey corporation business or gross income tax for qualified investments in an emerging technology business with a physical presence in New Jersey and that conducts research, manufacturing, or technology commercialization in the state. Any investor wishing to apply for the Angel Investor Tax Credit Program must submit a completed application, with all required documentation submitted by November 15, 2016 to be considered for approval for a 2016 tax credit certificate.

“When entrepreneurs like Jeong Kim and Wim Sweldens pitch to investors, they can point to the State’s Angel Investor Tax Credit Program as an added incentive to obtain funding,” EDA Chief Executive Officer Melissa Orsen said. “In just over three years since the program was established, investors have already pumped more than $142 million into New Jersey-based life sciences and technology companies like Kiswe.”

Sweldens and Kim bring extensive knowledge of the telecommunications industry and strong ties to New Jersey’s vibrant technology community to their position at the helm of the company. Kim served as President of Bell Labs and Sweldens served as President of Alcatel-Lucent’s wireless division.
 
“Founding Kiswe in New Jersey was a very natural decision made by the team, especially given the fact that we mostly hail from Bell Labs, located just around the corner from our first office,” Sweldens said. “We were already well acquainted with the incredible local talent pool as well as the wonderful quality of life this area offers.” 
 
Kiswe recently hired its 22^nd employee at its New Jersey headquarters and currently has satellite offices in New York, Maryland, Belgium and South Korea.

@NJEDATech asked Sweldens about Kiswe’s experience in New Jersey and its plans for the future.   

What does funding provided through the Angel Investor Tax Credit mean to Kiswe Mobile?
Funding provided by investors that participated in the Angel Investor Tax Credit Program has benefited Kiswe in every part of our business. Kiswe competes in the next big area of consumer and business technology — live streaming. Because of the large opportunity ahead of us, competition is steep, so speed is key. The funding we received through this program has allowed us to grow at a faster pace than we ever imagined. Our technology has been at the forefront, surpassing some of the technology we see from today's largest players such as Facebook and Twitter.

What is your company’s biggest success to date?
We recently launched our consumer app on iOS and Android, bringing the technology right to the everyday worldwide user. For the COPA America games, we leveraged our consumer app to drive engaging fan content produced by top soccer players. With the Kiswe app, approved producers are able to stream live, anytime, anywhere. In just a few short months, Kiswe has on-boarded a variety of top content providers from professional mixed martial arts leagues to top sports commentators. Our app users simply love using Kiswe to get insider access to live events. 

What’s in store for Kiswe Mobile in the near future?
With our innovative technology in-hand, the future for Kiswe is about growth in both our business and consumer tracks. If you are a broadcaster, content producer or advertiser looking to access the engaged mobile audience at Kiswe, please reach out to us at info@kiswe.com. If you are a consumer looking for engaging live and interactive content, please download the Kiswe app in the iOS or Android store. 
 
To learn more about the Angel Tax Credit Program and other resources available to New Jersey’s emerging technology and life sciences companies, visit https://www.njeda.gov/tls and follow @NJEDATech on Twitter and LinkedIn.

VectraCor President and Chief Executive Officer Brad S. Schreck

TRENTON (November 3, 2016) – New Jersey is known for its long history of innovation, and emerging companies like VectraCor are continuing that legacy. Based in Totowa, VectraCor has developed what it describes as the world’s first cardiac electrical biomarker (CEB®) that can help nurses and doctors more accurately detect and diagnose heart attacks, recognized as the number one killer in the world.

Traditional electrocardiograms (ECG) are used to monitor a patient’s heart and generate complex reports for a doctor’s analysis using 10 wires, or electrodes, to get 12 leads, or pictures of the heart. VectraCor’s proprietary product, VectraplexECG System with CEB®, provides 15 leads in the United States and 22 leads in Europe, giving nurses and doctors a more in-depth view of the patient’s heart. Additionally, because VectraplexECG System with CEB® uses only five electrodes, both patient preparation time and the potential for inaccurate placement of electrodes by nurses or technicians are greatly reduced. The technology also provides a report from which doctors and nurses can easily and quickly interpret whether a patient is having a heart attack, enabling them to get critical care that much faster.

VectraplexECG System with CEB is currently being used in Jersey City Medical Center, RWJBarnabas Health, Summit Medical Group and numerous urgent care centers throughout the State. VectraplexECG System with CEB is one of numerous products for which VectraCor has either patents or patents-pending in 12 countries.

“When patients are experiencing a heart attack, medical personnel need answers immediately,” VectraCor President and Chief Executive Officer Brad S. Schreck said. “That’s why hospitals and urgent care centers around New Jersey and throughout the world turn to VectraCor for fast and accurate reports.”

Schreck had an opportunity to pitch VectraCor and its technology to potential investors at the most recent New Jersey Founders & Funders event on Oct. 26. Hosted by the New Jersey Economic Development Authority (EDA), the semi-annual event enabled VectraCor and more than two dozen other companies to meet angel and venture capital investors in 10-minute, one-on-one “speed dating” sessions to discuss strategy, business models and funding opportunities.

Schreck also touted the fact that many of the company’s existing investors have benefited from the State’s Angel Investor Tax Credit Program. Administered by the EDA in consultation with the New Jersey Division of Taxation, the program offers a 10 percent refundable tax credit against New Jersey corporation business or gross income tax for qualified investments in an emerging technology business with a physical presence in New Jersey and that conducts research, manufacturing, or technology commercialization in the state. Any investor wishing to apply for the Angel Investor Tax Credit Program must submit a completed application, with all required documentation, by November 15, 2016 to be considered for approval of a 2016 tax credit certificate.

“VectraCor’s use of State resources to impact the global marketplace reinforces the positive effect New Jersey’s support has on growing technology companies,” EDA Chief Executive Officer Melissa Orsen said. “Groundbreaking technologies provided by companies like VectraCor are a testament to the pioneering companies that call New Jersey home, and the supportive ecosystem we offer to these innovative companies in all phases of their growth.”  

Schreck and his brother Dr. David Schreck founded VectraCor after extensive education from New Jersey schools. Both attended Stevens Institute of Technology, completing Bachelor of Science degrees in organic chemistry and Master of Engineering degrees in biomedical engineering. Brad also earned an MBA in marketing from Fairleigh Dickinson University.  

@NJEDATech spoke with Brad Schreck about VectraCor’s experience in New Jersey and upcoming plans:

Why did you choose to grow your company here in New Jersey?
David and I knew about the State’s long history of innovation and felt it appropriate to start VectraCor here. We were both born and raised in New Jersey and, although I have been relocated and have lived in many states, I feel right at home here and knew this was the perfect location to build our business. Additionally, the quality of the talent pool in New Jersey, particularly in the medical technology space, is very high, and that is important to the future success of our company.

What’s the best piece of advice you received at New Jersey Founders & Funders?
Investors were very encouraging about our business model and our product. They provided positive feedback and suggested we continue pitching to a wide array of investors to find the perfect match.

What is your company’s biggest success to date? 
The fact that we have potentially saved lives is one of our biggest accomplishments. I’m also proud of the fact that we took an idea from scratch and developed it into a product that received United States Food and Drug Administration approval and a Conformité Européenne (CE) Mark. A CE Mark is necessary for marketing products in Europe. I’m also extremely pleased that we have been able to generate revenue.

What’s on the horizon for VectraCor? 
We are in a growth phase and are looking to hire sales representatives across the country and throughout the world, as well as more support staff in New Jersey. The emergence of mobile health technology is very exciting to us and we are in the process of developing products in the mobile health sphere that will be used to save lives.

 

TRENTON (October 27, 2016) – When patients in the intensive care unit (ICU) develop severe deadly inflammation from life-threatening conditions, time is of the essence. Uncontrolled inflammation can rapidly lead to organ failure and death. This is when doctors turn to companies like Middlesex County-based CytoSorbents Corporation.

CytoSorbents, a Monmouth Junction medical device company focused on critical care immunotherapy, is commercializing a blood purification technology called CytoSorb® to reduce deadly inflammation common to many lethal conditions in the ICU such as sepsis and infection, trauma, liver failure, and complications of open heart surgery.

“CytoSorb® acts as a filter for your blood to remove a wide range of inflammatory substances from blood that fuel the fire of severe, body-wide inflammation,” CytoSorbents Chief Financial Officer Kathleen Bloch said. “Without treatment, patients often develop dangerous complications such as multiple organ failure, where the risk of death is extremely high. CytoSorb® is also being used to control severe inflammation generated during complex open heart surgery.”

CytoSorb®, which is reported to have been used safely in more than 14,000 human treatments to date, is currently approved in the European Union, and is being distributed in 40 countries around the world. Through a series of high-profile partnerships and agreements, CytoSorbents recently increased the global reach of its life-saving technology. In September, the company entered into a strategic partnership with Terumo Cardiovascular Group, a global leader in medical devices for cardiac and vascular surgery and subsidiary of Japan-based Terumo Corporation, to commercialize CytoSorb® for cardiac surgery applications in six countries in Europe. Terumo joins the list of existing strategic partners which include Fresenius Medical Care, the world’s largest dialysis company, and Biocon, the largest biopharmaceutical company in India. Most recently, the company announced that it had signed an agreement with medical device distributor Foxx Medical Chile SpA to distribute CytoSorb® in Chile, marking the first entry of CytoSorb® into the Americas.

CytoSorbents is currently conducting clinical trials to seek approval from the United States Food and Drug Administration (FDA) for use of CytoSorb® in cardiac surgery. The company recently completed a 40-patient feasibility and safety study called REFRESH (REduction in FREe Hemoglobin) I, demonstrating that intra-operative use of CytoSorb® in high risk cardiac surgery patients was safe, and plans to begin a pivotal registration trial in early 2017, designed to support U.S. regulatory approval by 2019.

CytoSorbents assembles and conducts all quality assurance and quality control on the CytoSorb® cartridge at their facility in New Jersey. The company employs approximately 70 people, with roughly two-thirds located at the Monmouth Junction facility.

“CytoSorbents is another example of a New Jersey company positively impacting critical care on the global stage,” New Jersey Economic Development Authority (EDA) Chief Executive Officer Melissa Orsen said. “Supporting these types of emerging businesses through all stages of growth remains at the core of the EDA’s mission.”

CytoSorbents has benefited significantly from EDA support. The company is a multi-year participant in the State’s Technology Business Tax Certificate Transfer (NOL) Program and was among 40 businesses recently approved to participate in this year’s program. Administered by the EDA and the New Jersey Department of Treasury's Division of Taxation, this competitive program enables eligible technology and biotechnology companies to sell New Jersey tax losses and/or research and development tax credits to raise non-dilutive cash to finance their growth and operations. 

Additionally, CytoSorbents was one of two dozen New Jersey companies to receive funding from the New Jersey Technology Council’s (NJTC) NJTC Fund 1, in which the EDA invested $7.15 million in a limited partnership investment. The EDA’s investment to the $70 million fund resulted in a public/private leverage multiplier of 51.76 times for the total $370 million of third party partner capital into New Jersey-based businesses. Earlier this month, the EDA announced approval for investment in Tech Council Ventures II, the NJTC’s newest venture fund. 

Last week, NJBIZ announced that Bloch was named as NJBIZ Public Company CFO of the Year.

@NJEDATech asked Bloch about her company’s experience in New Jersey and its plans for the future:

Why did CytoSorbents choose to locate in New Jersey?
We chose to move to New Jersey in 2001 to take advantage of available laboratory space and New Jersey’s excellent workforce. Being a research and development company, it was important to be able to attract top scientific talent and Monmouth Junction was ideal.

How does CytoSorbents benefit from State resources like the NOL Program?  
The NOL program has provided CytoSorbents with more than $2 million in total funding during the past five years. This program has enabled us to turn our operating losses into cash, and that cash was critical to our growth initiatives.

What’s on the horizon for CytoSorbents? 
We plan to continue growing our product sales in Europe and throughout the world, and expect to achieve operating profitability within approximately two years. Meanwhile, we plan to run our pivotal clinical trial here in the United States in cardiac surgery and, if successful, achieve FDA approval of CytoSorb® in the 2018 or 2019 timeframe, depending on the clinical path.  We look forward to bringing the story to life here at home and helping to improve clinical outcomes in cardiac surgery and critical illnesses in the United States.
 

Fusar Co-Founder Ryan Shearman credits the State's technology ecosystem with helping to build his company.

TRENTON (October 20, 2016) – Linking his enthusiasm for motorcycle riding with a desire to ensure the safety of fellow riders, New Jersey entrepreneur Ryan Shearman co-founded Fusar Technologies in 2013. Fusar develops technology that can turn regular helmets into smart helmets for cyclists, motorcyclists, skaters, skiers and snowboarders to use during their adventures. 

Fusar describes its Universal Smart Helmet System as “an action camera, communication system, navigation unit, black box and emergency response system all wrapped into one.” Among the wide variety of features available to adventure seekers, the FUSAR Camera can detect when a user has been in an accident, retroactively record the last two minutes of action before the accident, alert the person’s emergency contact and show that contact the user’s exact location through an interactive map.  Users can also take high-resolution photos and HD video with a push of a button during their adventures and share them through social or traditional media via the FUSAR app, which is now available on both iOS and Android. The technology also allows up to 12 people to chat via Bluetooth, no matter how far apart they are.

This summer, Fusar gained national exposure when it appeared on CNBC’s series premiere of “Adventure Capitalists,” in which adventure-related companies seek funding in a “Shark Tank” style show. Shearman, who is also Fusar’s Chief Executive Officer (CEO), made sure that the show promoted the fact that the company hailed from New Jersey.

“The New Jersey technology community has been part of our narrative since day one,” Shearman told @NJEDATech. “We wouldn’t be where we are today without the ample support from so many facets of the state’s technology sector.”

Fusar has benefited from multiple resources available to New Jersey’s emerging technology innovators through the State and other organizations invested in the industry’s success.

“New Jersey’s innovation ecosystem is built on the backs of those entrepreneurs who combine a personal passion with a desire to fill a gap in the marketplace,” New Jersey Economic Development Authority (EDA) CEO Melissa Orsen said. “In less than three years, Jersey City-based Fusar has grown into a company that exemplifies how small businesses can leverage public and private resources to grow and thrive in the Garden State.”

The company is one of 40 businesses that the EDA approved to share $35 million through the State’s Technology Business Tax Certificate Transfer (NOL) Program in Fiscal Year 2017. Administered by the EDA and the New Jersey Department of Treasury's Division of Taxation, this competitive program enables eligible technology and biotechnology companies to sell New Jersey tax losses and/or research and development tax credits to raise non-dilutive cash to finance their growth and operations. 

Fusar also participated in a New Jersey Founders & Funders event in 2014. Held at the EDA’s Commercialization Center for Innovative Technologies in North Brunswick, the event enables early-stage businesses to meet with potential investors in 10-minute, one-on-one “speed dating” sessions to discuss strategy, business models and funding opportunities.

Fusar is also a graduate of the TechLaunch accelerator’s third cohort. An added avenue for emerging technology companies as they grow, accelerators like TechLaunch can provide early-stage technology companies with capital, mentorship, business training, key services and exposure to qualified investors, which will increase their value as an enterprise and the likelihood of follow-on funding.

Additionally, the team’s first two rounds of funding were led by JumpStart New Jersey Angel Network, an active group of investors in early-stage technology ventures in the region and frequent New Jersey Founders & Funders participant. The EDA provided seed capital for both TechLaunch and JumpStart.

@NJEDATech spoke with Shearman about Fusar’s experience in New Jersey and its plans for the future:

Why did you choose to grow Fusar in New Jersey?
My co-founders and I all grew up in Bergen County, so the obvious choice for us was to make a go at starting a company here in our home state. When we learned about all of the great programs New Jersey has in place to help foster innovation, it made so much sense to us to stay on this side of the river instead of building our company in New York City.

What was the best piece of advice you received at NJ Founders and Funders?
We attended the New Jersey Founders & Funders event when we were still very young and hadn’t solidified our go-to-market strategy. One of the best takeaways from that day was that it was ok that our plan was still in flux and that we didn’t need to have answers for every single question at that early stage. It’s better to tell an investor that you don’t have all of the answers, as long as you know where to find them and can demonstrate that successfully.

What do you consider your company’s biggest success to date?
Shipping product. I’ve commercialized over one hundred consumer products for other companies during my career, but I will never forget the day that my co-founder and I dropped off our first batch of hardware products at the post office. We only shipped out a few dozen units that day, but it was the culmination of over two years of hard work, determination, and a lot of ramen noodles.

What’s on the horizon for Fusar?
We’re gearing up to put the FUSAR Camera in production, while at the same time trying to handle increasing demand from distributors and retailers both here in the U.S. and abroad. More and more people are learning about our products on a daily basis, which is fundamentally great, but that also brings new challenges. We’re going to have to raise our Series A financing in the not-so-distant future in order to support continued growth right here in the Garden State.

For more information about resources available to support New Jersey’s technology industry, visit https://www.njeda.gov/tls and follow @NJEDATech on Twitter and LinkedIn.
 

TRENTON (October 14, 2016) – Continuing its efforts to bolster innovation in the Garden State, the New Jersey Economic Development Authority (EDA) today approved its 14^th venture fund investment.  Action taken today will result in a limited partnership investment of up to $7.5 million in Tech Council Ventures II, which aims to invest in early-stage companies spanning key industries that are currently experiencing rapid growth.

“Since the days of Thomas Edison, New Jersey has always been a leader in innovation,” EDA Chief Executive Officer Melissa Orsen said. “Through investments in venture funds such as Tech Council Ventures II, the State routinely provides early-stage companies with much-needed capital that they can use to bring products to market or expand existing product lines. These investments have the dual benefit of keeping New Jersey at the forefront of innovation and creating jobs within the Garden State.”

Among its myriad of resources for the technology sector, the EDA helps increase available capital for emerging technology companies by investing as a limited partner in venture capital firms that invest in New Jersey-based enterprises. Investments made by the EDA are expected to earn a reasonable market rate return, which is measured in financial terms and by job growth. Gains resulting from these investments are utilized to offer new funding opportunities to support New Jersey businesses. Prior to today’s action, the EDA had approved investments in 13 venture capital funds totaling more than $42 million; these funds have leveraged the EDA’s investment in New Jersey technology businesses with private capital, by more than 62 times. The attraction of private investors into these companies demonstrates the credibility of the technology ecosystem in New Jersey and the attractiveness of investment opportunities in the state. 

Tech Council Ventures II is the second fund formed in sponsorship and strategic partnership with the New Jersey Technology Council (NJTC). Tech Council Ventures II will seek to invest in 20 to 25 early-stage companies with an average initial investment of $500,000 to $2 million in fast-growing sectors, such as healthcare information technology, life sciences, education technology, financial technology, media technology and energy.

The EDA supported the predecessor vehicle formed in 2000, NJTC Fund I, with a $7.15 million limited partnership investment. The EDA’s investment to the $70 million fund resulted in a public/private leverage multiplier of 51.76 times the total $370 million of third party partner capital into New Jersey-based businesses. The 24 New Jersey companies that benefited have generated an estimated 1,983 jobs in the State. Achieve 3000, located in Lakewood, Fairfield-based Archive Systems, Cytosorbents in Monmouth Junction, and Power Survey, of Kearny, are among the two-dozen New Jersey businesses that leveraged funding from NJTC Fund I to thrive in the Garden State.

"As the leading association supporting and advocating for the technology community in New Jersey, we see Tech Council Ventures as a critical component of the resources we offer to nurture early-stage technology startups,” said James Barrood, President and CEO of the NJ Technology Council. “We appreciate the strong support of the EDA and believe this fund will make a big difference to the state's ecosystem.”

To stimulate growth of New Jersey’s innovation economy and drive commercialization of pioneering technology within the state, the EDA offers a continuum of assistance specifically designed to help technology and biotechnology companies at every stage of growth. From networking and mentoring to financial assistance such as loans and tax credits, hundreds of entrepreneurs, emerging businesses and established companies benefit from EDA support each year. Examples of this support include the New Jersey Angel Investor Tax Credit Program, the State’s Technology Business Tax Certificate Transfer (NOL) Program and resources available through the EDA’s Commercialization Center for Innovative Technologies.

To learn about resources available to support the technology industry, visit https://www.njeda.gov/tls and follow @NJEDATech on Twitter and LinkedIn.

The EDA is part of the State’s results-driven Partnership for Action. Created by Governor Christie and led by Lt. Governor Guadagno, the Partnership is the hub for all economic development activity in New Jersey and is comprised of four interconnected and highly focused organizational elements: Choose New Jersey, the Business Action Center, the Office of the Secretary of Higher Education and the EDA. 

EDA Board meetings are typically held at 10 a.m. on the second Tuesday of each month at 36 West State Street in Trenton. The Board meeting schedule, as well as Board agendas and minutes, are available at www.njeda.gov. All Board actions will take effect at the expiration of the statutory period for the Governor’s review and consideration of the meeting minutes.
 

Michael J. Fox Foundation for Parkinson’s Research Chief Executive Officer Dr. Todd Sherer among headliners at the EDA's "Foundations are the New VCs Funding Panel" on Oct. 18.

North Brunswick, N.J. (October 13, 2016) – The Michael J. Fox Foundation for Parkinson’s Research (MJFF) Chief Executive Officer Dr. Todd Sherer and Andrea Yonah of the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation will headline a funding panel discussion at the New Jersey Economic Development Authority’s (EDA) Commercialization Center for Innovative Technologies (CCIT) on Oct. 18. The event is being held in partnership with BioNJ.

Entitled “Foundations are the New VCs,” the free event will encourage New Jersey biotechnology companies to explore alternative research and development (R&D) funding sources from foundations like MJFF and BIRD. It will also address questions such as:

• How will the next generation of drugs, diagnostics and devices be funded?
• What new funding models might change the paradigm?
• Is there an alternative way to fund early and emerging commercial biomedical research?

Dr. Sherer directs MJFF’s research strategy and is responsible for the Foundation’s overall scientific and fundraising direction to speed development of treatment and a cure for Parkinson’s disease. In 2015 alone, MJFF funded $87.8 million in research programs.

The BIRD Foundation works to encourage and facilitate cooperation between U.S. and Israeli companies in a wide range of technology sectors and offers funding to selected projects. Yonah noted that a pair of companies, one from the U.S. and one from Israel, can apply jointly for funding of up to 50 percent (maximum of $1 million) of the combined project budget. Since January 1, 2015, the BIRD Foundation has approved $23 million in funding for 28 projects, 11 of them in the life sciences sector.

Dr. Lisa Hague, Associate Manager of Technical Support at GENEWIZ, will also participate in the panel and will focus on how GENEWIZ benefited from the BIRD Foundation’s support. GENEWIZ is a CCIT graduate.
Biotechnology companies interested in attending can register online at https://www.njeda.gov/Press-Room/Events/CCIT-Foundations-are-the-New-VCs.

The event, which will be held from 3:00 p.m. to 5:00 p.m., is part of the EDA’s ongoing efforts to provide exposure to funding opportunities for New Jersey’s technology community.

“We often hear from the technology community how critical funding is to continuing development,” EDA CEO Melissa Orsen said. “That’s why the EDA frequently hosts opportunities, like the event on Oct. 18 and our New Jersey Founders and Funders event later this month, through which entrepreneurs can connect with those who can guide them to much needed capital.”

The event will also give biotechnology companies the chance to visit CCIT, a 46,000-square-foot incubator that is home to nearly two dozen businesses. With 27 wet labs and access to offices, conference rooms, a supportive staff and a variety of additional resources, CCIT is ideal for emerging companies looking to grow in the Garden State. CCIT is located within the Technology Centre of New Jersey, a 75-acre research park that houses such companies as Chromocell and Orthobond (both of which are CCIT graduates), Allergan, and Merial.  Companies interested in touring CCIT should visit   www.njeda.gov/CCIT or contact Lenzie Harcum at lharcum@njeda.com.

For more information about resources available to support New Jersey’s technology industry, visit https://www.njeda.gov/tls and follow @NJEDATech on Twitter and LinkedIn.
 

The New Jersey Economic Development Authority's next public Board Meeting will be held on Friday, October 14, 2016 at 10 a.m. at the EDA offices at 36 West State Street, Trenton. A copy of the proposed agenda can be found prior to the meeting at www.njeda.gov/Board. Following the Board Meeting, minutes and the full agenda will also be available at www.njeda.gov/Board.

A Special Meeting of the New Jersey Economic Development Authority has been scheduled for Friday September 30, 2016 at 11:00 a.m. in our offices at 36 West State Street, Trenton NJ. The Members will meet to discuss and act upon a request from Liberty Property Trust, Camden Waterfront Project, Closing Deadline Extension Request. The agenda can be found 48 hours prior at www.njeda.gov/Board.